AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

PEPFAR: Two Million People at an Undisclosed PriceThin moat

Gilead Sciences (GILD) — moat facet

Gilead will supply lenacapavir PrEP for up to two million people through PEPFAR, a customer that buys for access at a price Gilead does not disclose.

Gilead's most ambitious customer relationship for lenacapavir is with a government aid programme. In 2025 it announced a partnership with the US State Department and PEPFAR to deliver lenacapavir for PrEP "for up to two million people over three years" in countries supported by both PEPFAR and the Global Fund1.

Gilead rest-of-world sales, 2025 ($M)3,483All products1,456HIV1,190BiktarvyGilead Form 10-K FY2025, revenue by product and geography
The aid programme sits beside a $3.5 billion paying market.

That is a different kind of customer. PEPFAR buys to prevent infection in poor countries, and Gilead does not disclose the price. The revenue will be small next to the volume: Gilead's entire rest-of-world product sales were $3,483 million in 20252, and its rest-of-world HIV sales $1,456 million3.

Why do it? A medicine taken by two million people builds clinical experience, manufacturing scale and political standing, which matter when the same government sets Medicare prices at home. It also builds the record that sells Yeztugo in the markets that pay full price: Yeytuo received European marketing authorisation for PrEP in 20254.

The relationship carries one commercial risk. A very low price in aid markets can become a reference point in negotiations elsewhere, and Gilead's December 2025 agreement already returns "a portion of increased international revenues" to the United States in certain conditions5.

PEPFAR is not Gilead's only government-aid relationship. In 2026 it announced a donation of 2,000 vials of remdesivir to Uganda6. Such programmes build standing with the governments that also regulate and pay for Gilead's medicines, which is part of why a company so dependent on public payers keeps doing them.

The partnership works if volume reaches people and revenue grows in paying markets alongside it. If Gilead's rest-of-world product sales fall in 2026 or 2027 while PEPFAR volume ramps, the aid price will be leaking into commercial ones.

Moat trajectory: Holding steady

Partnership announced 2025; rest-of-world product sales $3,483M in 2025.

The number that tests this moat
Reported
Rest-of-world product sales, full year
$3,483M (2025)

The paying markets outside the US and Europe; a fall while aid volume grows would mean the aid price is leaking.

Source: Gilead Sciences Form 10-K, FY2025 ↗
References
  1. ReportedIn 2025 it announced a partnership with the US State Department and PEPFAR to deliver lenacapavir for PrEP "for up to two million people over three years" in countries supported by both PEPFAR and the Global Fund.
    Gilead Sciences third-quarter 2025 results release, Form 8-K exhibit 99.1 - the Biktarvy settlements, the PEPFAR lenacapavir partnership and the chief executive's statement on exclusivity. — Q3 2025 · publ. 30 October 2025 · source ↗
  2. ReportedThe revenue will be small next to the volume: Gilead's entire rest-of-world product sales were $3,483 million in 2025, and its rest-of-world HIV sales $1,456 million.
    Gilead Sciences Form 10-K for 2025 - revenue by product, product group and region (Note 2) and the MD&A discussion of product sales. — FY2025 · publ. 24 February 2026 · source ↗
  3. ReportedThe revenue will be small next to the volume: Gilead's entire rest-of-world product sales were $3,483 million in 2025, and its rest-of-world HIV sales $1,456 million.
    Gilead Sciences Form 10-K for 2025 - revenue by product, product group and region (Note 2) and the MD&A discussion of product sales. — FY2025 · publ. 24 February 2026 · source ↗
  4. ReportedIt also builds the record that sells Yeztugo in the markets that pay full price: Yeytuo received European marketing authorisation for PrEP in 2025.
    Gilead Sciences third-quarter 2025 results release, Form 8-K exhibit 99.1 - the Biktarvy settlements, the PEPFAR lenacapavir partnership and the chief executive's statement on exclusivity. — Q3 2025 · publ. 30 October 2025 · source ↗
  5. ReportedA very low price in aid markets can become a reference point in negotiations elsewhere, and Gilead's December 2025 agreement already returns "a portion of increased international revenues" to the United States in certain conditions.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  6. ReportedIn 2026 it announced a donation of 2,000 vials of remdesivir to Uganda.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
Sources
Generated October 4, 2026